Monograph

A10BH02 - Vildagliptin

Propably not porphyrinogenic

Rationale

Vildagliptin is not a CYP substrate and has no capacity for inhibition or induction of the major CYP-subclasses. There are no pharmacokinetic drug interactions with vildagliptin as perpetrator.

Chemical description

Hydroxy admantan amino acetyl pyrrolidine carbonitrile

Therapeutic characteristics

Vildagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. It can be used as mono therapy or as part of combination therapy with other anti-diabetic drugs. Vildagliptin increases the levels of endogenous incretin hormones via potent and selective inhibition of dipeptidyldipeptidase-4 (DPP-4). Nausea is a common side effect of vildagliptin that may potentially be porphyrinogenic through reduction in carbohydrate intake.

Metabolism and pharmacokinetics

Vildagliptin is not a CYP substrate; it is metabolized by hydrolysis mainly in the kidneys. It is devoid of capacities for induction or inhibition of any of the CYP-subclasses. There are no pharmacokinetic interactions with vildagliptin as perpetrator.

Similar drugs

Explore alternative drugs in similar therapeutic classes A10B / A10BH or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Golightly LK, Drayna CC, et al. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
2.	Clinical pharmacokinetics and pharmacodynamics of vildagliptin. He YL. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62.	22339447
3.	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Scheen AJ. Diabetes Obes Metab. 2010 Aug; 12(8):648-58.	20590741
*	Summary of Product Characteristics
4.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Galvus.

Citation details

PMID

Scientific articles

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Golightly LK, Drayna CC, et al. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.

Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

He YL. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62.

22339447

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ. Diabetes Obes Metab. 2010 Aug; 12(8):648-58.

20590741

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Galvus.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames